1-3 of 3
Elena Henkel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Sabine Kahl, Sofiya Gancheva, Klaus Straßburger, Christian Herder, Jürgen Machann, Hisayuki Katsuyama, Stefan Kabisch, Elena Henkel, Stefan Kopf, Merit Lagerpusch, Konstantinos Kantartzis, Yuliya Kupriyanova, Daniel Markgraf, Theresa van Gemert, Birgit Knebel, Martin F. Wolkersdorfer, Oliver Kuss, Jong-Hee Hwang, Stefan R. Bornstein, Christian Kasperk, Norbert Stefan, Andreas Pfeiffer, Andreas L. Birkenfeld, Michael Roden
Journal: Diabetes Care
Diabetes Care 2020;43(2):298–305
DOI: https://doi.org/10.2337/dc19-0641
Published: 20 September 2019
View article titled, Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Click here to open pdf in another window PDF for Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Andrew J. Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G. Holst, Miriam P. Annett, Vanita R. Aroda
Journal: Diabetes Care
Diabetes Care 2018;41(2):258–266
DOI: https://doi.org/10.2337/dc17-0417
Published: 15 December 2017
View article titled, Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Click here to open pdf in another window PDF for Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Includes: Supplementary data
Journal Articles

Insulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study

Markolf Hanefeld, MD, PHD, Carsta Koehler, PHD, Katja Fuecker, DIPL CHEM, Elena Henkel, MD, Frank Schaper, MD, Theodora Temelkova-Kurktschiev, MD, PHD
Journal: Diabetes Care
Diabetes Care 2003;26(3):868–874
DOI: https://doi.org/10.2337/diacare.26.3.868
Published: 01 March 2003
View article titled, Insulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: <span class="subtitle">The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study</span>
Click here to open pdf in another window PDF for Insulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: <span class="subtitle">The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study</span>